Seattle, Jan. 02, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global enteral syringe market is estimated to be valued at US$ 575.6 million in 2017, and is projected to exhibit a CAGR of 4.9% over the forecast period (2018 – 2026).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/enteral-syringe-market-2398

Key Trends and Analysis of the enteral syringe market:

Enteral syringes are majorly used for administering drugs and nutritional therapy through oral, rectal or sublingual route of administration. They are commonly used in hospitals, clinics, and homes, available in range of 1ml to 60 ml. Drugs can be directly placed into the gastro-intestinal tract through enteral route. Enteral syringes are most widely used for delivering oral liquid medication and nutrition. Enteral syringes come with purple plunger, which indicates that the medication in the syringe must be administered via enteral route. Purple color is used in order to separate these syringes from IV syringes. These syringes are helpful in correct measurement of liquid medicine to be administered to patient in situation where dose cannot be accurately measured using a medicine cup or spoon, for administering medicine to infants and young children, and administering controlled drug liquid medicines. These syringes are available in different types such as single use syringes and reusable enteral syringes and home use syringes. 

Various factors responsible for the growth of enteral syringe market are increasing number of critical care and neonatal intensive care unit admissions, updated regulatory guidelines for enhanced safety features associated with enteral syringe, increasing geriatric population worldwide and new products launched by key players in the enteral syringe market. According to statistics presented by Bliss Organization, over 95,000 newborns are admitted to neonatal units in the U.K, annually due to premature birth (before 37 weeks of pregnancy) or due to full term (after 37 weeks) yet sick birth. Moreover, according to same source around 1 in every 8 newborns in the U.K are admitted to neonatal units, annually. ENFit is a new connection standard that is developed by an international group of clinicians, manufacturers body Global Enteral Device Supplier Association (GEDSA), and regulators under aegis of Stay Connected initiative to prevent tubing misconnections and patient injury. This would help in safe use of enteral syringe and better adoption of them in clinical practice. Based on this design, various companies are launching new enteral syringes. In February 2017, Baxter International Inc. launched new enteral ENFit syringe and accessory line for patients requiring tube feeding. Baxter’s new enteral ENFit syringes are designed to improve patient safety during enteral nutrition (EN) therapy by preventing misconnections or wrong-route administration that can cause severe patient injury.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2398

Key Market Takeaways:

• The enteral syringe market is expected to exhibit a CAGR of 4.9% during the forecast period (2018– 2026), estimated to reach US$ 885 by 2026.
• Market growth is attributed to are increasing number of critical care and neonatal intensive care unit admissions, updated regulatory guidelines for enhanced safety features associated with enteral syringe, increasing geriatric population worldwide and new products launched by key players in the market
• Some of the major players operating in the global enteral syringe market include B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A., and others.